

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 1 of 1	ATTORNEY DOCKET No.	SERIAL No.
	6170-000010/US	10/591,174
	APPLICANT	
	Jan GUNZINGER et al.	
	FILING DATE	GROUP
	August 30, 2006	1614

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.						

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
2.							

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
1.		Carlos L. Arteaga et al., "Growth Inhibition of Human Breast Cancer Cells <i>in Vitro</i> with an Antibody Against the Type I Somatomedin Receptor", <i>Cancer Res.</i> , Vol. 49, pp. 6237-6241 (Nov. 15, 1989).
2.		D. D. De Leon et al., "Effects of Insulin-Like Growth Factors (IGFs) and IGF Receptor Antibodies on the Proliferation of Human Breast Cancer Cells", <i>Growth Factors</i> , Vol. 6, pp. 327-336 (1992).
3.		David W. Andrews et al., "Results of a Pilot Study Involving the Use of an Antisense Oligonucleotide Directed Against the Insulin-Like Growth Factor Type I Receptor in Malignant Astryctomas", <i>J. Clin. Onc.</i> , Vol. 19, No. 8, pp. 2189-2200 (Apr. 15, 2001).
4.		P.J. White et al., "Antisense Inhibition of IGF Receptor Expression in HaCaT Keratinocytes: A Model for Antisense Strategies in Keratinocytes", <i>Antisense & Nuc. Acid Drug Dev.</i> , Vol. 10, pp. 195-203 (2000).
5.		Diane Prager et al., "Dominant negative inhibition of tumorigenesis <i>in vivo</i> by human insulin-like growth factor I receptor mutant", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 2181-2185 (Mar. 1994).
6.		Krzysztof Reiss et al., "Inhibition of Tumor Growth by a Dominant Negative Mutant of the Insulin-Like Growth Factor I Receptor with a Bystander Effect", <i>Clin. Cancer Res.</i> , Vol. 4, pp. 2647-2655 (Nov. 1998).
7.		Laura K. Shawver et al., "Receptor Tyrosine kinases as targets for inhibition of angiogenesis", <i>DDT</i> , Vol. 2, No. 2, (Feb. 1997).
8.		Jane Pritchard et al., "Synovial Fibroblasts from Patients with Rheumatoid Arthritis, Like Fibroblasts from Graves' Disease, Express High Levels of IL-16 When Treated with Igs against Insulin-Like Growth Factor-1 Receptor", <i>J. Immun.</i> , pp. 3564-3569 (2004).
9.		A.J. Salisbury et al., "Development of Molecular Agents for IGF Receptor Targeting", <i>Horm. Metab. Res.</i> , Vol. 35, pp. 843-849 (2003).
10.		Constantine S. Mitsiades et al., "Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors", <i>Cancer Cell</i> , Vol. 5, pp. 221-230 (Mar. 2004).

Examiner: /Zinna Davis/ (12/14/2009)

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ZD/